Science 37 Holdings Debt 2024

Science 37 Holdings Aktienanalyse

What does Science 37 Holdings do?

Science 37 Holdings Inc. is a company specializing in clinical trials supported by technology and digital methods. It was founded in 2014 by a team of experienced medical and technological experts. The company is headquartered in Los Angeles, California, USA. Science 37's business model focuses on accelerating clinical trials and reducing costs by facilitating access to patients and data through a digital, telemedicine-based infrastructure. This is changing the way clinical trials are conducted by addressing one of the biggest obstacles to industrial development: the lengthy recruitment of patients. The various divisions of Science 37 include a platform for telemedicine studies, which allows virtual researchers to assess and connect with patients remotely, an in-house platform for clinical data management and analysis, and an extensive network of physicians and patients who offer and participate in clinical studies. Science 37's partners include pharmaceutical companies, biotech companies, academic institutions, and government agencies. Science 37 offers a wide range of products tailored to the specific needs of its customers. These products include: 1. NORA - A telemedicine platform for near-site recruitment, which allows patients to conveniently participate in a clinical trial through their own device. The platform provides a seamless and integrated experience for the patient and facilitates collaboration between study centers and virtual researchers. 2. NEST - A platform for clinical studies designed for the management of large data-driven studies. NEST provides a central database that simplifies the collection and management of study data and complies with compliance requirements. 3. SIV - A cloud-based platform for site initiation visits, which allows sponsors to accelerate study initiation with a wealth of site information without the need for an on-site visit. 4. Decentralized Clinical Trials - A fully digital platform that supports a clinical study from recruitment to data analysis and uses the "bring your own device" paradigm (BYOD). Decentralized Clinical Trials allow access from anywhere, whenever the patient desires. The company has an impressive track record, having worked on more than 27 clinical trials and being awarded numerous accolades, including "Most Innovative Clinical Trial Solution Provider" at the Global Health & Pharma (GHP) Awards 2019. Overall, Science 37 is an innovative company that has revolutionized the way clinical trials are conducted. Technology has the potential to radically transform medical research and accelerate drug development. Science 37 is pushing the boundaries of what is possible in large-scale patient recruitment and is a key player in the digital transformation of clinical research. Science 37 Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Science 37 Holdings's Debt Structure

Science 37 Holdings's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Science 37 Holdings's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Science 37 Holdings’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Science 37 Holdings’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Science 37 Holdings stock

What is the debt of Science 37 Holdings this year?

Science 37 Holdings has a debt level of -108.1 USD this year.

What was the debt of Science 37 Holdings compared to the previous year?

The debt of Science 37 Holdings has increased by -49.63% compared to the previous year dropped.

What are the consequences of high debt for investors in Science 37 Holdings?

High debt can pose a risk for investors of Science 37 Holdings, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Science 37 Holdings?

Low debt means that Science 37 Holdings has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Science 37 Holdings affect the company?

An increase in debt of Science 37 Holdings can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Science 37 Holdings affect the company?

A reduction in debt of Science 37 Holdings can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Science 37 Holdings?

Some factors that can influence the debt of Science 37 Holdings include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Science 37 Holdings so important for investors?

The debts of Science 37 Holdings are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Science 37 Holdings take to change the debt?

To change the debt, Science 37 Holdings can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Science 37 Holdings pay?

Over the past 12 months, Science 37 Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Science 37 Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Science 37 Holdings?

The current dividend yield of Science 37 Holdings is .

When does Science 37 Holdings pay dividends?

Science 37 Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Science 37 Holdings?

Science 37 Holdings paid dividends every year for the past 0 years.

What is the dividend of Science 37 Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Science 37 Holdings located?

Science 37 Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Science 37 Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Science 37 Holdings from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Science 37 Holdings pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Science 37 Holdings in the year 2023?

In the year 2023, Science 37 Holdings distributed 0 USD as dividends.

In which currency does Science 37 Holdings pay out the dividend?

The dividends of Science 37 Holdings are distributed in USD.